HRP20120160T1 - Supstituirani fenoksi n-alkilirani tiazoldindion kao modulatori estrogen srodnih alfa-receptora - Google Patents

Supstituirani fenoksi n-alkilirani tiazoldindion kao modulatori estrogen srodnih alfa-receptora Download PDF

Info

Publication number
HRP20120160T1
HRP20120160T1 HR20120160T HRP20120160T HRP20120160T1 HR P20120160 T1 HRP20120160 T1 HR P20120160T1 HR 20120160 T HR20120160 T HR 20120160T HR P20120160 T HRP20120160 T HR P20120160T HR P20120160 T1 HRP20120160 T1 HR P20120160T1
Authority
HR
Croatia
Prior art keywords
benzonitrile
phenoxy
trifluoromethyl
ethyl
ylidenemethyl
Prior art date
Application number
HR20120160T
Other languages
English (en)
Croatian (hr)
Inventor
Gaul Michael
Lee Searle Lily
Rentzeperis Dionisios
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20120160T1 publication Critical patent/HRP20120160T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20120160T 2007-03-07 2008-03-06 Supstituirani fenoksi n-alkilirani tiazoldindion kao modulatori estrogen srodnih alfa-receptora HRP20120160T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89345807P 2007-03-07 2007-03-07
PCT/US2008/056018 WO2008109731A2 (en) 2007-03-07 2008-03-06 Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators

Publications (1)

Publication Number Publication Date
HRP20120160T1 true HRP20120160T1 (hr) 2012-03-31

Family

ID=39720674

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120160T HRP20120160T1 (hr) 2007-03-07 2008-03-06 Supstituirani fenoksi n-alkilirani tiazoldindion kao modulatori estrogen srodnih alfa-receptora

Country Status (26)

Country Link
US (2) US8119669B2 (OSRAM)
EP (1) EP2132188B1 (OSRAM)
JP (1) JP2010520307A (OSRAM)
KR (1) KR20090118103A (OSRAM)
CN (1) CN101679326B (OSRAM)
AR (1) AR065656A1 (OSRAM)
AT (1) ATE537157T1 (OSRAM)
AU (1) AU2008222749A1 (OSRAM)
BR (1) BRPI0808662B8 (OSRAM)
CA (1) CA2679965A1 (OSRAM)
CL (1) CL2008000669A1 (OSRAM)
CY (1) CY1112778T1 (OSRAM)
DK (1) DK2132188T3 (OSRAM)
EA (1) EA200970838A1 (OSRAM)
ES (1) ES2377165T3 (OSRAM)
HR (1) HRP20120160T1 (OSRAM)
IL (1) IL200758A0 (OSRAM)
MX (1) MX2009009519A (OSRAM)
NZ (1) NZ579418A (OSRAM)
PL (1) PL2132188T3 (OSRAM)
PT (1) PT2132188E (OSRAM)
RS (1) RS52247B (OSRAM)
SI (1) SI2132188T1 (OSRAM)
TW (1) TW200902507A (OSRAM)
WO (1) WO2008109731A2 (OSRAM)
ZA (1) ZA200906953B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
MX2009009517A (es) * 2007-03-07 2009-09-16 Janssen Pharmaceutica Nv Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno.
ES2365966T3 (es) 2007-09-14 2011-10-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas.
WO2009033703A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
BRPI0816767B8 (pt) 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
US7973062B2 (en) * 2008-02-22 2011-07-05 The Ohio State University Research Foundation Androgen receptor-ablative agents
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
BRPI0920354A2 (pt) 2008-10-16 2017-06-27 Addex Pharmaceuticals Sa derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP2011057644A (ja) * 2009-09-14 2011-03-24 Sumitomo Chemical Co Ltd ３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物
JP2011057643A (ja) * 2009-09-14 2011-03-24 Sumitomo Chemical Co Ltd ３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物
KR20130001242A (ko) 2010-02-17 2013-01-03 얀센 파마슈티카 엔.브이. 에스트로겐 관련 수용체-알파 조절제로서의 아미노티아졸론
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PT2649069E (pt) 2010-11-08 2015-11-20 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2012153775A1 (ja) * 2011-05-10 2012-11-15 国立大学法人神戸大学 Ras機能阻害作用を有するチオキソチアゾリジン誘導体
TW201311679A (zh) 2011-08-04 2013-03-16 Takeda Pharmaceutical 含氮雜環化合物
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
CA2868311C (en) 2012-03-26 2021-06-22 Nippon Chemiphar Co., Ltd. Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma
EP2909333A1 (en) * 2012-10-17 2015-08-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for predicting and treating bone metastases in prostate cancer patients
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3050573B1 (en) 2013-09-25 2019-12-11 Nippon Chemiphar Co., Ltd. Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma
HUE045610T2 (hu) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk
PH12021552653A1 (en) 2014-01-21 2023-07-17 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
CA3002709A1 (en) 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
EP3840749B1 (en) * 2018-08-22 2023-08-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compounds for treating cardiac valve disease
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN112538038B (zh) * 2019-09-20 2022-05-20 暨南大学 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
HK1043113A1 (zh) * 1999-07-01 2002-09-06 Geron Corporation 端粒酶抑制劑及其使用方法
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
WO2001078721A1 (en) 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
US7348348B2 (en) * 2002-04-30 2008-03-25 Merck & Co. Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2006004555A1 (en) 2004-06-30 2006-01-12 Paysetter Pte Ltd System and method for facilitating transfer of physical money and/or credit
US20060014812A1 (en) * 2004-07-14 2006-01-19 Player Mark R Use of estrogen related receptor-modulating aryl ethers
US7977489B2 (en) 2004-10-22 2011-07-12 Exelixis, Inc. Benzylthiazolone inhibitors of estrogen-related receptors (ERR)

Also Published As

Publication number Publication date
RS52247B (sr) 2012-10-31
CN101679326A (zh) 2010-03-24
EA200970838A1 (ru) 2010-02-26
AR065656A1 (es) 2009-06-24
BRPI0808662B1 (pt) 2020-09-29
ES2377165T3 (es) 2012-03-23
IL200758A0 (en) 2010-05-17
EP2132188A2 (en) 2009-12-16
CN101679326B (zh) 2012-12-12
US20080286265A1 (en) 2008-11-20
ZA200906953B (en) 2010-12-29
BRPI0808662B8 (pt) 2021-05-25
NZ579418A (en) 2012-01-12
DK2132188T3 (da) 2012-02-27
SI2132188T1 (sl) 2012-04-30
PL2132188T3 (pl) 2012-05-31
WO2008109731A2 (en) 2008-09-12
US9034852B2 (en) 2015-05-19
KR20090118103A (ko) 2009-11-17
EP2132188B1 (en) 2011-12-14
CY1112778T1 (el) 2016-02-10
US20120108571A1 (en) 2012-05-03
TW200902507A (en) 2009-01-16
AU2008222749A1 (en) 2008-09-12
MX2009009519A (es) 2009-11-18
BRPI0808662A2 (pt) 2014-08-26
ATE537157T1 (de) 2011-12-15
JP2010520307A (ja) 2010-06-10
US8119669B2 (en) 2012-02-21
CA2679965A1 (en) 2008-09-12
CL2008000669A1 (es) 2008-11-03
PT2132188E (pt) 2012-02-13
WO2008109731A3 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
HRP20120160T1 (hr) Supstituirani fenoksi n-alkilirani tiazoldindion kao modulatori estrogen srodnih alfa-receptora
JP2010520307A5 (OSRAM)
JP2010520308A5 (OSRAM)
JP2010520306A5 (OSRAM)
JP2014516953A5 (OSRAM)
CA2566945A1 (en) Pyrazole derivatives, compositions containing such compounds and methods of use
RU2014127686A (ru) Антагонисты pcsk9
JP2010508359A5 (OSRAM)
JP2010530438A5 (OSRAM)
RU2014103587A (ru) Производные циклических аминов в качестве антагонистов рецептора ер4
JP2009522292A5 (OSRAM)
JP2009533410A5 (OSRAM)
ME02439B (me) Odredjeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe
RU2014119711A (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
JP2010508358A5 (OSRAM)
AR065657A1 (es) DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS.
HRP20140919T1 (hr) Spojevi koji moduliraju androgene receptore
JP2014051526A5 (OSRAM)
HRP20170997T1 (hr) Asimetrične uree i njihove medicinske uporabe
RU2003132687A (ru) Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
JP2007508361A5 (OSRAM)
JP2011515482A5 (OSRAM)
JP2016500063A5 (OSRAM)
JP2008521827A5 (OSRAM)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物